Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines

The inhibitory epidermal growth factor receptor (EGFR) antibody, cetuximab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC). Despite tumor response observed in some HNSCC patients, cetuximab alone or combined with radio- or chemotherapy fails to yield long-term control or cu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Pharmacol
Autores principales: Hinz, Trista K., Kleczko, Emily K., Singleton, Katherine R., Calhoun, Jacob, Marek, Lindsay A., Kim, Jihye, Tan, Aik Choon, Heasley, Lynn E.
Formato: Artigo
Lenguaje:Inglês
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2019
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7385532/
https://ncbi.nlm.nih.gov/pubmed/31554698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.119.117804
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares